TY - JOUR
T1 - Long-term tolerability of fenretinide (4-HPR) in breast cancer patients
AU - Rotmensz, N.
AU - De Palo, G.
AU - Formelli, F.
AU - Costa, A.
AU - Marubini, E.
AU - Campa, T.
AU - Crippa, A.
AU - Danesini, G. M.
AU - Delle Grottaglie, M.
AU - Di Mauro, M. G.
AU - Filiberti, A.
AU - Gallazzi, M.
AU - Guzzon, A.
AU - Magni, A.
AU - Malone, W.
AU - Mariani, L.
AU - Palvarini, M.
AU - Perloff, M.
AU - Pizzichetta, M.
AU - Veronesi, U.
PY - 1991
Y1 - 1991
N2 - A group of 53 patients initially participating in a phase I trial with the synthetic retinoid fenretinide was assessed for the long-term tolerability of this compound. The patients were evaluated after 42 months of drug intake at a dose of 200 mg/day, including a 3-day drug interruption at the end of each month, by the following examinations: a dermatological visit; an ophthalmological evaluation including an ophthalmological questionnaire and an electroretinogram (ERG); a study on blood chemistry and plasma retinol levels; a study on bone densities and on skeletal X-rays; and finally a psychological evaluation including various tests for anxiety, depression and overall mood. The results show that prolonged administration of fenretinide is well tolerated. No acute nor severe toxicity was observed and thus this compound can be considered a good candidate for chemoprevention trials in a variety of patient populations.
AB - A group of 53 patients initially participating in a phase I trial with the synthetic retinoid fenretinide was assessed for the long-term tolerability of this compound. The patients were evaluated after 42 months of drug intake at a dose of 200 mg/day, including a 3-day drug interruption at the end of each month, by the following examinations: a dermatological visit; an ophthalmological evaluation including an ophthalmological questionnaire and an electroretinogram (ERG); a study on blood chemistry and plasma retinol levels; a study on bone densities and on skeletal X-rays; and finally a psychological evaluation including various tests for anxiety, depression and overall mood. The results show that prolonged administration of fenretinide is well tolerated. No acute nor severe toxicity was observed and thus this compound can be considered a good candidate for chemoprevention trials in a variety of patient populations.
UR - http://www.scopus.com/inward/record.url?scp=0025745286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025745286&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(91)90309-2
DO - 10.1016/0277-5379(91)90309-2
M3 - Article
C2 - 1835622
AN - SCOPUS:0025745286
VL - 27
SP - 1127
EP - 1131
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 9
ER -